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1. Introduction 
Inhibitors of microtubule polymerization are some of the most 
common and effective treatment for breast cancer.1 Colchicine, 
vinca alkaloids, and taxol are known as typical microtubule 
inhibitors of natural product origin. Many kinds of inhibitors of 
microtubules bind to either the colchicine binding site,2 the 
vinblastine binding site,3 or the taxoid binding site4 in α,β-tubulin. 
Especially, taxanes and vinca alkaloids, such as taxol and 
vinblastine, are used in cancer chemotherapy. In contrast, 
inhibitors binding to the colchicine site has not been used in 
clinic at the present, although these compounds are currently 
undergoing clinical development and evaluation in patients with 
a wide array of cancers. 
Glaziovianin A (1), a naturally occurred isoflavone derivative, 
is an inhibitor of microtubule dynamics (Fig. 1).5,6 Previously, we 
reported the synthesis7 and structure–activity relationship study8 
of glaziovianin A (1). In that report, we revealed that O7-
alkylated9 glaziovianin A analogues have strong cytotoxicity 
against HeLa cells. Especially, O7-propargyl glaziovianin A (2) 
indicated more potent cytotoxic effects8b than glaziovianin A (1) 
itself and decreased the polymerization rate of α,β-tubulin in 
vitro.6 We also revealed, from the results of a competition assay, 
that glaziovianin A (1) binds to the colchicine site of α,β-
tubulin.6  
In a series of structure–activity relationship studies of 
glaziovianin A (1), we reported the synthesis of O7-benzyl 
glaziovianin A (3), which showed strong cytotoxicity against 
HeLa cells (IC50 = 0.19 µM).8 On the other hand, we recently 
developed a modified route to the synthesis of O7-modified 
glaziovianin A.7b However, the resultant O7-benzyl glaziovianin 
A (3) showed much weaker cytotoxicity (IC50 = 12.81 µM). We 
supposed that the previous lot of O7-benzyl glaziovianin A (3) 
contained an impurity that exhibits strong cytotoxicity. In this 
paper, we described the discovery of a new glaziovianin A 
derivative: O6-benzyl glaziovianin A (4), which showed more 
potent cytotoxicity against HeLa cells and inhibitory activity of 
polymerization of α,β-tubulin than known α,β-tubulin inhibitors, 
such as colchicine and glaziovianin A (1). 
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We have discovered O6-benzyl glaziovianin A, which showed stronger inhibition of microtubule 
polymerization (IC50 = 2.1 µM) than known α,β-tubulin inhibitors, such as colchicine and 
glaziovianin A. Also, we performed competition binding experiments of O6-benzyl glaziovianin 
A and revealed that O6-benzyl glaziovianin A binds to the colchicine binding site with high 
affinity. It is interesting that glaziovianin A derivatives change their mode of action in 
benzylation at the O6 (α,β-tubulin inhibitor) or O7 (γ-tubulin-specific inhibitor) position. 
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Figure 1. Structures of glaziovianin A (1) and its derivatives. 
 
2. Results and Discussion 
2.1. Discovery of O6-benzyl glaziovianin A (4) 
We used HPLC analysis to examine the purities of old and 
new lots of O7-benzyl glaziovianin A (3) (Fig. 2). As a result, the 
previously synthesized O7-benzyl glaziovianin A (3) contained an 
impurity (ca. 10%). In contrast, the new lot of O7-benzyl 
glaziovianin A (3) did not contain this impurity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HPLC analysis of O7-benzyl glaziovianin A (3); upper: 
preparation by the previous synthetic route; bottom: preparation by the 
modified synthetic route (column: Develosil ODS-HG-5 (φ4.6 × 250 mm), 
solvent: 75% MeOH aq., detect: UV 254 nm, flow rate: 1 mL/min). 
 
Next, we isolated the impurity in previously synthesized O7-
benzyl glaziovianin A (3) by using preparative HPLC and 
determined its structure. The molecular weight of the impurity 
was identical to that of O7-benzyl glaziovianin A (3) by ESIMS 
analysis. Also, we compared the 1H NMR data between the 
impurity and O7-benzyl glaziovianin A (3) (Table 1). The 
chemical shifts of the protons at the A-ring portion (H1–H4) in the 
impurity were different from those of O7-benzyl glaziovianin A 
(3), and the others corresponded well (within 0.01 ppm). These 
results suggested that the impurity was an isomer of O7-benzyl 
glaziovianin A (3) concerning the A-ring, such as O6-benzyl 
glaziovianin A (4). Thus, we planned to rigorously synthesize O6-
benzyl glaziovianin A (4) to confirm the structure of the impurity. 
 
Table 1 1H NMR data of A-ring of O7-benzyl glaziovianin A 
(3) and the impurity (600 MHz, CD3OD) 
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No. O
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glaziovianin A (3) impurity 
H1 7.58 7.64 
H2 7.22 7.18 
H3 5.27 5.21 
H4 3.95 4.01 
 
We synthesized O6-benzyl glaziovianin A (4) according to our 
established strategy (Scheme 1). To convert commercially 
available sesamol (5) to known benzophenone 6, we followed the 
procedure reported by Tamura et al.10 Regioselective methylation 
of benzophenone 6 gave the desired monomethyl benzophenone 
7,11 which was converted into benzyl ether 8. Condensation of 8 
with N,N-dimethylformamide dimethyl acetal afforded enamine 9, 
which was transformed into iodochromone 10. The Suzuki–
Miyaura coupling reaction12 between iodochromone 10 and 
pinacol boronate 117b furnished O6-benzyl glaziovianin A (4). 
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Scheme 1. Synthesis of O6-benzyl glaziovianin A (4). 
Reagents and conditions: (a) MeI, K2CO3, acetone, 60 °C; (b) 
BnCl, K2CO3, n-Bu4NI, MeCN, rt, 35% in two steps; (c) 
(MeO)2CHNMe2, 95 °C; (d)  I2, py, CHCl3, rt, 86% in two 
steps; (e) 11, PdCl2(dppf)·CH2Cl2, 1 M Na2CO3 aq, 1,4-
dioxane, rt, 76%. 
 
The 1H NMR data of the impurity were in good agreement 
with those of synthetic O6-benzyl glaziovianin A (4) (Fig. 3). 
Therefore, the structure of the impurity was confirmed to be O6-
benzyl glaziovianin A (4).13 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3 1H NMR (600 MHz, CD3OD) spectra of the impurity and of 
synthetic O6-benzyl glaziovianin A (4). 
 
2.2. Biological activity of O6-benzyl glaziovianin A (4) 
We next evaluated the cytotoxicity of O6-benzyl glaziovianin 
A (4), O7-benzyl glaziovianin A (3), and glaziovianin A (1) 
against HeLa cells (Table 2) and the effects on the microtubule 
polymerization (Fig. 4). Glaziovianin A (1) showed moderate, 
and O7-benzyl glaziovianin A (3) weak cytotoxicity against HeLa 
cells. In contrast, O6-benzyl glaziovianin A (4) showed potent 
cytotoxicity (IC50 = 0.07 µM). 
 
Table 2 Cytotoxicity of colchicine and glaziovianin A 
derivatives against HeLa cells 
compound IC50 (µM) 
colchicine 0.02 ± 0.01 
glaziovianin A (1) 0.61 ± 0.07 
O7-benzyl glaziovianin A (3) 12.81 ± 6.26 
O6-benzyl glaziovianin A (4) 0.07 ± 0.01 
 
Previously we reported that glaziovianin A (1) and O7-
propargyl glaziovianin A (2) decreased the in vitro 
polymerization rate of α,β-tubulin.6 In the present study, we used 
microtubule polymerization to examine whether O6-benzyl 
glaziovianin A (4) also inhibits microtubule dynamics. As shown 
in Fig. 4A, pure O7-benzyl glaziovianin A (3) showed no 
apparent effects, but O6-benzyl glaziovianin A (4) completely 
inhibited microtubule polymerization at the concentration of 3 
µM. In the same condition, colchicine also inhibited microtubule 
polymerization, but less potently compared with O6-benzyl 
glaziovianin A (4) (Fig. 4B). The IC50 values for O6-benzyl 
glaziovianin A (4) and colchicine were 2.1 ± 0.7 and 9.1 ± 1.3 
µM, respectively (Fig. 4B), suggesting that O6-benzyl 
glaziovianin A (4) is a more potent microtubule inhibitor than 
colchicine in vitro. Furthermore, the previous lot of O7-benzyl 
glaziovianin A (3) (before HPLC separation) still showed an 
intermediate inhibitory effect on microtubule polymerization (Fig. 
4A). Therefore, we concluded that contaminating O6-benzyl 
glaziovianin A (4) in the previous lot of O7-benzyl glaziovianin 
A (3) caused considerable inhibitory activity against microtubule 
polymerization and cell proliferation.14 
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Figure 4. Effects of glaziovianin A derivatives on microtubule 
polymerization. Purified porcine tubulin was incubated with or without each 
compound at 37 °C and then polymerized by the addition of 10 µM taxol (A) 
or 1 M glutamate (B). A. O6-Benzyl glaziovianin A (4) inhibited microtubule 
polymerization at 3 µM, but the O7-derivative did not. ○: DMSO control; ●: 
O7-benzyl glaziovianin A (3), which was prepared by the previous synthetic 
route (before HPLC separation); ■: HPLC-separated O7-benzyl glaziovianin A 
(3); and □: HPLC-separated O6-benzy glaziovianin A (4). B. O6-Benzyl 
glaziovianin A (4) inhibited microtubule polymerization in a dose-dependent 
manner. Effects of O6-benzyl glaziovianin A (4), prepared by the modified 
synthetic route, on microtubule polymerization in vitro. The final 
concentrations were 0 µM (○), 0.5 µM (▲), 1.5 µM (△), and 3.0 µM (♦) of 
O6-benzyl glaziovianin A (4), 5 µM (■) and 30 µM (□) of colchicine, or 10 
µM of glaziovianin A (1) (●). 
 
2.3. Competition binding experiments of O6-benzyl glaziovianin 
A (4) 
We previously reported that glaziovianin A (1) and O7-
propargyl glaziovianin A (2) decreased the in vitro 
polymerization rate of α,β-tubulin by binding to the colchicine 
binding site.6 To determine whether the binding site of O6-benzyl 
glaziovianin A (4) is the same as that of glaziovianin A (1), we 
performed competition binding experiments using [3H]-labeled 
vinblastine and colchicine (Table 3). Like colchicine and 
glaziovianin A (1), O6-benzyl glaziovianin A (4) inhibited the 
binding of [3H]-colchicine but enhanced the binding of [3H]-
vinblastine, suggesting that the binding site of O6-benzyl 
glaziovianin A (4) is identical or close to those of colchicine and 
glaziovianin A (1). Furthermore, the changes in tryptophan 
fluorescence showed that O6-benzyl glaziovianin A (4) bound to 
α,β-tubulin with a markedly higher affinity than glaziovianin A 
(1) and colchicine (Table 4). These results strongly suggest that 
O6-benzyl glaziovianin A (4) binds to the colchicine binding site 
with high affinity and inhibits microtubule polymerization more 
potently than colchicine and glaziovianin A (1). 
Table 3 Inhibitory effects of O6-benzyl glaziovianin A (4) on 
the binding of colchicine and vinblastine to tubulin 
 radiolabelled drug bound (% of control) 
compound [3H]-colchicine [3H]-vinblastine 
colchicine 18.2 ± 1.1 151.9 ± 6.8 
vinblastine 127. 1 ± 9.7 5.3 ± 0.5 
glaziovianin A (1) 67.8 ± 7.1 112.4 ± 5.5 
O6-benzyl 
glaziovianin A (4) 20.3 ± 1.5 117.7 ± 4.4 
The competition assay of O6-benzyl glaziovianin A (4) 
binding to tubulin with radiolabelled vinblastine or colchicine 
was monitored by the centrifugal gel filtration method. Values 
are the means ± s.d. 
 
Table 4 Drug binding analysis based on tryptophan 
fluorescence spectrum changes 
compound Kd (µM) 
colchicine 26.6 ± 13.4 
glaziovianin A (1) 80.0 ± 45.7 
O6-benzyl glaziovianin A (4) 1.0 ± 0.1 
The Kd value of each drug was calculated from the tryptophan 
fluorescence decrease (∆FL) from three independent experiments 
using GraphPad Prizm software. Values are the means ± s.d. 
 
2.4. Effects of O6-benzyl glaziovianin A (4) on the cell cycle 
progression and spindle structure in mitosis 
We next examined the effects of O6-benzyl glaziovianin A (4) 
on the cell cycle progression and spindle structure in mitosis (Fig. 
5). O6-Benzyl glaziovianin A (4) completely inhibited the cell 
cycle progression in mitosis at 10 times lower concentrations 
than glaziovianin A (1) did (Fig. 5, Left). Under this condition, 
O6-benzyl glaziovianin A (4) inhibited the normal bipolar spindle 
formation (Fig. 5, Right). Most of the cells treated with 100 nM 
O6-benzyl glaziovianin A (4) showed a multipolar spindle as the 
glaziovianin A (1)-treated cells did. At higher concentrations, O6-
benzyl glaziovianin A (4) completely disrupted the microtubule 
and only short fragments were observed. These results also 
indicate that O6-benzyl glaziovianin A (4) is a potent microtubule 
polymerization inhibitor. 
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Figure 5. Effects of O6-benzyl glaziovianin A (4) on cell cycle 
progression (Left) and spindle morphology (Right). Left: Effects of 
colchicine, glaziovianin A (1) and O6-benzyl glaziovianin A (4) on cell cycle 
progression in HeLa cells. HeLa cells were treated with each compound for 
18 h. Right: Effects of colchicine, glaziovianin A (1) and O6-benzyl 
glaziovianin A (4) on spindle morphology in HeLa cells. HeLa cells were 
treated with glaziovianin A (1) and O6-benzyl glaziovianin A (4) for 6 h. 
Scale bar, 20 µm. Green and blue represent α-tubulin and DNA, respectively. 
 
3. Conclusions 
In conclusion, we have discovered O6-benzyl glaziovianin A 
(4), which showed stronger inhibition of microtubule 
polymerization than known α,β-tubulin inhibitors, such as 
colchicine and glaziovianin A (1).15 O6-Benzyl glaziovianin A (4) 
potently inhibited microtubule polymerization in vitro (IC50 = 2.1 
µM) and arrested cell cycle progression in mitosis by forming 
abnormal spindles, suggesting that the introduction of a benzyl 
group at the O6 position potentiates the affinity to the colchicine 
binding site of α,β-tubulin. Although O6-benzyl glaziovianin A 
(3) inhibited microtubule polymerization in vitro more potently 
than colchicine, the cytotoxicity of O6-benzyl glaziovianin A (3) 
was weaker than that of colchicine, suggesting that cell 
permeability of O6-benzyl glaziovianin A (3) is lower than that of 
colchicine.  
We recently reported glaziovianin A (1) and O7-propargyl 
glaziovianin A (2) as microtubule dynamics inhibitors,6 and O7-
benzyl glaziovianin A (3) as a γ-tubulin-specific inhibitor, 
gatastatin.14 Our preliminary data suggested that O6-benzyl 
glaziovianin A (4) also inhibits GTP binding on γ-tubulin (89.6 ± 
1.7% inhibition at 60 µM). This inhibitory activity was weaker 
than that of O7-benzyl glaziovianin A (3) (93.3 ± 3.7% inhibition 
at 60 µM).  Thus, it is interesting that glaziovianin A derivatives 
change their mode of action in benzylation at the O6 (α,β-tubulin 
and γ-tubulin inhibitor) or O7 (γ-tubulin-specific inhibitor) 
position (Fig. 6).14b Here we showed that glaziovianin A (1) is 
good template with which to develop tubulin superfamily 
inhibitors. The synthesis of O6-modified glaziovianin A 
derivatives is currently underway in our group. 
 
 
 
 
 
 
 
 
 
 
 
MeO
O O
O
O
O
OMe
OMe
O
MeO O
O
O
O
OMe
OMe
O6-benzyl glaziovianin A (3)
α,β-tubulin polymerization inhibition
γ-tubulin interaction
O7-benzyl glaziovianin A (4)
γ-tubulin-specific interaction 
and nucleation inhibition
6
7
MeO
MeO O
O
O
O
OMe
OMe
6
7
glaziovianin A (1)
microtubule dynamics inhibition
weak γ-tubulin interaction
 
Figure 6 Summary of the structure–activity relationships of glaziovianin 
A derivative. 
 
4. Experimental 
4.1. Chemistry 
General method 
All moisture-sensitive reactions were performed under an 
atmosphere of argon or nitrogen, and the starting materials were 
azeotropically dried with benzene or toluene before use. 
Anhydrous acetone, MeCN, CHCl3, and 1,4-dioxane were 
purchased from Kanto Chemical Co., Inc., or Wako Pure 
Chemical Industries Ltd., and used without further drying. TLC 
analyses were conducted on E. Merck precoated silica gel 60 F254 
(0.25 mm layer thickness). Merck silica gel 60 (0.040–0.063 mm 
230–400 mesh) and Fuji Silysia silica gel BW-820MH (75–200 
µm) were used for column chromatography. Melting points were 
measured on Yanaco MP-J3 micro melting point apparatus and 
are uncorrected. Infrared (IR) spectra were recorded on a JASCO 
FT/IR-4100 instrument and only selected peaks are reported in 
wavenumbers (cm−1). 1H and 13C NMR spectra were recorded on 
a Varian INOVA-600 spectrometer, a Varian Mercury-400 
spectrometer, a Bruker AVANCE 600 spectrometer, a Bruker 
AVANCE 400 spectrometer or a Bruker DPX 400 spectrometer. 
The 1H and 13C chemical shifts were referenced to the solvent 
peaks, δH 7.26 (residual CHCl3) and δC 77.0 ppm (CDCl3), or δH 
3.31 (residual CHD2OD) and δC 49.0 ppm (CD3OD), respectively. 
J values are given in Hz. The following abbreviations are used 
for spin multiplicity: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, and br = broad. High resolution ESI/TOF 
This is an author version based on a template by Elsevier.
mass spectra were recorded on a JEOL AccuTOFCS JMS-
T100CS spectrometer. 
 
4 .1 .1 .  1-(5- (benzy loxy) -2-hydroxy-4-
methoxypheny l )e than-1-one  (8 )  
To a stirred solution of benzophenone 6 (103 mg, 0.61 mmol) 
in acetone (3.0 mL) were added K2CO3 (172 mg, 1.25 mmol) and 
MeI (40 µL, 0.64 mmol) at room temperature. After being stirred 
at reflux for 4 h, the reaction mixture was concentrated. The 
resultant mixture was dissolved in H2O (1.0 mL), diluted with 2 
M HCl (0.3 mL) to pH 3, and extracted with EtOAc (3 × 12 mL). 
The combined extracts were washed with brine, dried (Na2SO4), 
filtered, and concentrated to give a crude monomethyl 
benzophenone 7 (110 mg), which was used for the next reaction 
without further purification. 
To a stirred solution of the crude monomethyl benzophenone 
7 (110 mg) in MeCN (3.0 mL) were added K2CO3 (165 mg, 1.19 
mmol), BnCl (80 µL, 0.700 mmol), and n-Bu4NI (329 mg, 0.89 
mmol) at room temperature. After being stirred at room 
temperature for 8.5 h, the reaction mixture was filtrated with 
Celite, and this Celite was rinsed with EtOAc (4 × 10 mL). The 
filtrate and rinse were concentrated. The residual solid was 
purified by column chromatography on silica gel (10 g, hexane–
EtOAc 16:1→14:1→12:1→2:1) to give acetophenone 8 (57.3 mg, 
35% in two steps) as a white solid; mp 147–149 °C; IR (CHCl3) 
3025, 3012, 1633, 1508, 1444, 1374, 1329 cm–1; 1H NMR (400 
MHz, CDCl3) δ 12.59 (s, 1H), 7.45–7.32 (m, 5H), 7.09 (s, 1H), 
6.46 (s, 1H), 5.08 (s, 2H), 3.92 (s, 3H), 2.44 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 202.1, 160.4, 157.7, 140.4, 136.8, 128.6 
(2C), 128.1, 127.6 (2C), 116.2, 111.7, 100.6, 72.6, 56.1, 26.2; 
HRMS (ESI) m/z 271.1001, calcd for C16H15O4 [M–H]– 271.0975. 
 
4 .1 .2 .  6-(benzy loxy) -3- iodo-7-methoxy-4H-chromen-
4-one  (10 )  
Acetphenone 8 (6.5 mg, 24 µmol) was dissolved in N,N-
dimethylformamide dimethyl acetal (0.10 mL, 0.75 mmol) and 
stirred at 95 °C for 2 h. The reaction mixture was concentrated in 
vacuo to give crude enamine 9 (10 mg), which was used for the 
next reaction without further purification.  
To a stirred solution of crude enamine 9 (10 mg) in CHCl3 
(0.4 mL) were added pyridine (4.0 µL, 50 µmol) and I2 (9.5 mg, 
37 µmol) at 0 °C. After being stirred in dark at room temperature 
for 15 h, the mixture was diluted with saturated aqueous Na2S2O3 
(1 mL) at 0 °C and extracted with CHCl3 (4 × 3 mL). The 
combined extracts were washed with brine, dried (Na2SO4), 
filtered, and concentrated. The residual solid was purified by 
column chromatography on silica gel (700 mg, CHCl3) to give 
iodochromone 10 (8.4 mg, 86% in two steps) as a yellow solid: 
mp 129–132 °C; IR (CHCl3) 3012, 1634, 1618, 1505, 1448, 1287, 
1270 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.58 (s, 
1H), 7.47 (d, J = 7.2 Hz, 2H), 7.39–7.28 (m, 3H), 6.86 (s, 1H), 
5.21 (s, 2H), 3.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.4, 
156.9, 155.3, 152.4, 147.2, 136.0, 128.7 (2C), 128.2, 127.7 (2C), 
115.1, 107.0, 99.6, 86.6, 71.2, 56.5.; HRMS (ESI) m/z 430.9744, 
calcd for C17H13NaIO4 [M+Na]+ 430.9750. 
 
4 .1 .3 .  O 6 -benzy l  g laz iov ian in  A  (4 )  
All solvents were degassed by freeze–thawing. To a stirred 
solution of pinacol boronate 11 (8.4 mg, 24 µmol), iodochromone 
10 (8.0 mg, 20 µmol), and PdCl2(dppf)·CH2Cl2 (3.5 mg, 4.3 
µmol) in 1,4-dioxane (450 µL) was added aqueous 1 M Na2CO3 
(150 µL, 150 µmol) at room temperature in a glove box. The 
mixture was stirred at room temperature under a stream of N2 for 
20 h and diluted with H2O (1.0 mL) and CHCl3 (3.0 mL) at room 
temperature. The layers were separated, and the aqueous layer 
was extracted with CHCl3 (3 × 3.0 mL). The organic layer and 
extracts were combined, washed with brine, dried (Na2SO4), 
filtered, and concentrated. The residual solid was purified by 
column chromatography on silica gel (700 mg, hexane–EtOAc 
4:1→1:1) to give O6-benzyl glaziovianin A (4) (containing Pd-
metal). The resultant mixture was dissolved in CHCl3 (3 mL), 
and SiliaBond (SILICYCLE, SiliaMetS® Thiourea, 10 mg) was 
added. The resulting mixture was stirred at room temperature for 
12 h, filtered, and concentrated. The resultant mixture was 
purified by recycle HPLC [JAIGEL-1H-40 (φ20 × 600 mm) and 
JAIGEL-2H-40 (φ20 × 600 mm); flow rate 3.8 mL/min; 
detection, UV 254 nm; solvent CHCl3] to give O6-benzyl 
glaziovianin A (4) (6.3 mg, 68%) as a white solid: mp 185–
188 °C; IR (CHCl3) 3026, 3003, 1636, 1606, 1506, 1451, 1296, 
1270 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.89 (s, 1H), 7.71 (s, 
1H), 7.48 (d, J = 7.2 Hz, 2H), 7.40–7.28 (m, 3H), 6.89 (s, 1H), 
6.52 (s, 1H), 6.02 (s, 2H), 5.22 (s, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 
3.85 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 175.4, 154.9, 153.5, 
152.5, 146.8, 139.2, 139.0, 137.1, 136.8, 136.2, 128.7 (2C), 128.2, 
127.7 (2C), 121.7, 118.1, 117.8, 110.2, 107.0, 101.9, 99.8, 71.1, 
60.2, 56.9, 56.4; HRMS (ESI) m/z 485.1215, calcd for 
C26H22NaO8 [M+Na]+ 485.1206. 
 
4.2. Biology 
4 .2 .1 .  Calcu la t ion  o f  IC 5 0  va lue  
HeLa cells were grown in DMEM supplemented with 10% 
FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin in a 
humidified atmosphere containing 5% CO2. Various 
concentrations of each compound were then added and incubated 
for 48 hours. Cell growth was determined using WST-8 cell 
counting kit (Dojindo) and IC50 value was calculated. 
 
4 .2 .2 .  In  v i t ro  tubu l in  po lymer iza t ion  assay  
MAPs free α,β-tubulin was purified from porcine brain using 
two cycles of polymerization-depolymerization in a high-
molarity buffer as described previously.16 1 mg/mL α,β-tubulin, 
1 M glutamate and 1 mM GTP were mixed in RB buffer (100 
mM MES (pH 6.8), 1 mM EGTA, 0.5 mM MgCl2). One of the 
compounds was then added and incubated for 10 min on ice. 
Samples were transferred into cuvette and tubulin polymerization 
was determined by monitoring the absorbance at 350 nm at 37 °C 
using a thermostatic spectrophotometer (Beckman Coulter). The 
IC50 values for O6-benzyl glaziovianin A (4) and colchicine were 
calculated from final tubulin polymerization rate (control %) at 
20 min of each concentration. 
 
4 .2 .3 .  Compet i t ion  assay  
The competition assay of O6-benzyl glaziovianin A (4) 
binding to tubulin with radiolabelled vinblastine or colchicine 
was monitored by the centrifugal gel filtration method. The 
reaction mixture (50 µL) containing 0.5 mg/mL (approx. 5 µM) 
tubulin, 50 nM [3H]-labeled vinblastine or colchicine, 10% (v/v) 
DMSO and 100 µM mitotic inhibitor was incubated for 5 min at 
room temperature and processed by centrifugal gel filtration 
using Centri-Spin 20 (Princeton Separations). 
 
4 .2 .4 .  K d  va lue  ca lcu la t ion  
This is an author version based on a template by Elsevier.
Tryptophan fluorescence-based drug binding was performed 
as described in ref. 17 with minor modification. In briefly, 0.1 
mg/mL α,β-tubulin and 1 mM GTP were mixed in RB buffer 
(100 mM MES (pH 6.8), 1 mM EGTA, 0.5 mM MgCl2). Various 
concentrations of test compounds were then added and incubated 
for 30 min at room temperature. Samples were transferred into 
cuvette and tryptophan fluorescence of tubulin (excitation: 295 
nm, emission: 310–450 nm) was monitored using RF-5300 
(SHIMADZU). Dissociation constants were calculated from 
fitting curves of decreasing fluorescence using GraphPad Prizm. 
 
4 .2 .5 .  Analys i s  o f  ce l l  cyc le  progress ion  
HeLa cells were grown in DMEM supplemented with 10% 
FBS, 100 units/mL penicillin and 100 µg/mL streptomycin in a 
humidified atmosphere containing 5% CO2. Various 
concentrations of test compounds were then added and incubated 
for 18 hours. Cells were collected and fixed with 70% EtOH at –
20 °C. After wash with PBS, cells were stained with PI solution 
(0.2% NP-40, 0.1% trisodium citrate dehydrate, 71.1 µM 
propidium iodide and 10 µg/mL RNaseA) at 4 °C. DNA contents 
were analysed by cytometric analysis (PARTEC CyFlow PA; 
Partec GmbH, Munster, Germany). Cell populations of each cell 
cycle phase were calculated using Multi Cycle AV (PhoenixFlow 
Systems). 
 
4 .2 .6 .  Observa t ion  o f  mi to t ic  sp ind le  
HeLa cells were grown in DMEM supplemented with 10% 
FBS, 100 units/mL penicillin and 100 µg/mL streptomycin in a 
humidified atmosphere containing 5% CO2. Various 
concentrations of test compounds were then added and incubated 
for 6 hours. Cell growth was then fixed with cold MeOH (–
20 °C). Cells were blocked with 0.5% bovine serum albumin and 
incubated with anti-α-tubulin antibody (1:500 dilution, Santa 
Cruz, sc-32293) for 1 h at 37 °C. After staining with Alexa488-
conjugated anti-mouse IgG (1:2000 dilution, Invitrogen) for 30 
min at 37 °C, coverslips were washed with PBS and mounted 
PBS containing 0.1 µg/mL DAPI. Microtubule cytoskeleton was 
observed under the LAS AF 6000 fluorescence microscope 
(Leica Microsystems). 
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